| Wednesday
| Friday | Saturday
| Sunday |
| THURSDAY, DECEMBER
13, 2007 |
| 8:30-8:55 |
WELCOME – Exhibit Hall
D |
|
| |
Opening Remarks
Charles A. Coltman, Jr., MD
C. Kent Osborne, MD
|
|
| |
|
|
| 8:55-9:15 |
PLENARY LECTURE 1 – Exhibit Hall
D |
|
| |
|
|
| |
The worldwide overview: new results for systemic adjuvant therapies
Richard Peto, for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
University of Oxford
Oxford, UNITED KINGDOM
|
|
| |
|
|
| 9:15-10:30 |
GENERAL SESSION 1–
Exhibit Hall D |
|
| |
Hope Rugo, MD, Co-Moderator
UCSF Comprehensive Cancer Center,
San Francisco, CA
and
Eric Winer, MD, Co-Moderator
Dana Farber Cancer Institute,
Boston, MA |
|
| |
|
|
| 9:15 |
10. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100).
|
|
| |
Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, Yoshizawa C, Baehner F, Davidson N, Sledge G, Winer E, Hudis C, Ingle J, Perez E, Pritchard K, Shepherd L, Allred C, Osborne K, Hayes D. Southwest Oncology Group and The Breast Cancer Intergroup of NA, San Antonio, TX. |
|
| |
|
|
| 9:30 |
11. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials.
|
|
| |
Berry DA, Ueno NT, Johnson MM, Lei X, Lopez V, Caputo J, Bregni M, Demirer T. MDACC-EBMT Meta-Analysis Group, Houston, TX. |
|
| |
|
|
| 9:45 |
12. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older.
|
|
| |
Jones S, Holmes F, O'Shaughnessy J, Blum J, Vukelaj S, McIntyre K, Pippen J, Bordelon J, Kirby R, Sandbach J, Hyman W, Khandelwal P, Negron A, Richards D, Mennel R, Boehm K, Meyer W, Asmar L, Muss H, Savin M. US Oncology Research, Inc., Houston, TX; Vermont Cancer Center, Burlington, VT. |
|
| |
|
|
| 10:00 |
13. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease.
|
|
| |
Slamon DJ, Mackey J, Robert N, Crown J, Martin M, Eiremann W, Pienkowski T, Bee V, Taupin H, Villalobos I, Lindsay M-A, Riva A, Hurvitz S, Glaspy J, Pauletti G, Sauter G, Press M. Cancer International Research Group (CIRG), Edmonton, AB, Canada. |
|
| |
|
|
| 10:15 |
14. Outcome of breast cancer therapies for adjuvant versus advanced disease: how much do they differ? Critical comments towards the present process of randomized trials as a pre-requisite for adjuvant therapy guidelines.
|
|
| |
Ragaz J, Spinelli JJ. McGill University Health Centre, Montreal, QC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada.
|
|
| |
|
|
| 10:30-12:00 |
MINI-SYMPOSIUM 1 – Exhibit Hall
D |
|
| |
|
|
| |
STEMS CELLS IN BREAST CANCER
Jenny Chang, MD, Co-Moderator
Baylor College of Medicine, Houston, TX
and
Michael Lewis, PhD, Co-Moderator
Baylor College of Medicine, Houston, TX |
|
| |
|
|
| 10:30 |
Introduction |
|
| |
|
|
| 10:30 |
Breast cancer stem cell: Targets for prevention & therapy
Max Wicha , MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI
|
|
| |
|
|
| 11:00 |
Cancer stem cells in therapeutic resistance and as cellular targets
Jeremy Rich, MD
Duke University Medical Center
Durham, NC
|
|
| |
|
|
| 11:30 |
Epigenetic stem cell signatures in breast cancer |
|
| |
Peter Laird, PhD
USC/Norris Comprehensive Cancer Center
Los Angeles, CA |
|
| |
|
|
| 12:00-1:00 |
LUNCH [Ticket Required] – Exhibit
Hall A |
|
| |
|
|
| 1:00-1:30 |
PLENARY LECTURE 2 – Exhibit Hall D |
|
| |
|
|
| |
Radiation treatment planning for breast cancer: A journey through time |
|
| |
Lori Pierce, MD
University of Michigan Medical School
Ann Arbor, MI |
|
| |
|
|
| 1:30-3:45 |
GENERAL SESSION 2–
Exhibit Hall D |
|
| |
Mitchell Dowsett, MD, Co-Moderator
Royal Marsden Hospital,
London, UNITED KINGDOM
and
Richard Crownover, MD, PhD, Co-Moderator
Cancer Therapy and Research Center,
San Antonio, TX |
|
| |
|
|
| 1:30 |
21. Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer. |
|
| |
Whelan T, Pignol JP, Julian J, Grimard L, Bowen J, Perera F, Schneider K, Fyles A, Gulavita S, Shelley W, Freeman C, Szechtman B, Levine M. Juravinski Cancer Centre, Hamilton, ON, Canada; McMaster University, Hamilton, ON, Canada; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Ottawa Regional Cancer Centre, Ottawa, ON, Canada; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; London Regional Cancer Centre, London, ON, Canada; Windsor Regional Cancer Centre, Windsor, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern Regional Cancer Centre, Thunder Bay, ON, Canada; Kingston Regional Cancer Centre, Kingston, ON, Canada; McGill University Health Centre, Montreal, QC, Canada.
|
|
| |
|
|
| 1:45 |
22. dHER2 cancer immunotherapeutic: clinical response in breast cancer patients is associated with an induction of functional antibodies and the generation of specific T cells.
|
|
| |
Limentani SA, Curigliano G, Campone M, Dorval T, Romieu G, Vogel C, White S, de Boer R, Lehmann F, Cormont F, Louahed J. Blumenthal Cancer Center, Charlotte, NC; Ist Eur Oncol, Milan, Italy; Cent R Ganducheau, Nantes, France; Inst Curie, Paris, France; CRLCC, Montpellier, France; Cancer Res Network, Boca Raton, FL; Austin Hosp, Heidelberg, Australia; Royal Melbourne Hosp, Parkville Vic, Australia; GSK Bio, Rixensart, Belgium.
|
|
| |
|
|
| 2:00 |
23. Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. |
|
| |
Kuter I, Hegg R, Singer CF, Badwe R, Lowe E, on behalf of the NEWEST investigators. Massachusetts General Hospital, Boston, MA; University of Sao Paulo & Perola Bygton Hospital, Sao Paulo, Brazil; Medical University of Vienna, Vienna, Austria; Tata Memorial Hospital, Mumbai, India; AstraZeneca, Wilmington, DE.
|
|
| |
|
|
| 2:15 |
24. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells.
|
|
| |
Borley AC, Barrett-Lee PJ, Gee JMW, Shaw VE, Nicholson RI, Hiscox SE. Velindre Cancer Centre, Cardiff, United Kingdom; Tenovus Centre for Cancer Research, Cardiff, United Kingdom.
|
|
| |
|
|
| 2:30 |
25. The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy.
|
|
| |
Banerjee SN, Thornhill A, Evans DB, Littlewood-Evans AJ, Dowsett M, Martin L-A. Institute of Cancer Research, London, United Kingdom; Novartis Institute for BioMedical Research-Basel, Basel, Switzerland. |
|
| |
|
|
| 2:45 |
26. Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid - new results from ABCSG-12. |
|
| |
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kaessmann H, Piswanger-Soelkner C, Seifert M, Schippinger W, Menzel C, Dubsky P, Fitzal F, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Jakesz R, on behalf of the ABCSG. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
|
|
| |
|
|
| 3:00 |
27. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. |
|
| |
Brufsky A, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong M, Warsi G, Lacerna L, Perez E. Z-FAST Study Group; Novartis Pharmaceuticals, East Hanover, NJ. |
|
| |
|
|
| 3:15 |
28. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). |
|
| |
Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman R, Eastell R, Howell A. Wolfson Institute of Preventive Medicine, London, United Kingdom; Kings College School of Medicine, London, United Kingdom; University of Leeds, United Kingdom; Weston Park Hospital, Sheffield, United Kingdom; Christie Hospital, Manchester, United Kingdom; Northern General Hospital, Sheffield, United Kingdom. |
|
| |
|
|
| 3:30 |
29. Risk stratification based on the CYP2D6 tamoxifen metabolizing gene within the Italian tamoxifen prevention trial. |
|
| |
Serrano D, Bonanni B, Maisonneuve P, Johansson H, Macis D, Guerrieri-Gonzaga A, Basso D, Zambon C, Plebani M, Nicoloff M, Fontecha M, Hillman G, Wieczorek L, Rotmensz N, Decensi A. European Institute of Oncology (EIO); EIO, Milan, Italy; University-Hospital of Padova, Padova, Italy; Roche Molecular Diagnostics, Pleasanton, CA; E.O. Ospedali Galliera, Genova, Italy. |
|
| |
|
|
| 3:45-5:00 |
SUSAN G. KOMEN FOR THE CURE
BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES– Exhibit
Hall D
|
|
| |
|
|
| 3:45 |
"Omics" research in individualized breast cancer treatment - letting the tumors teach
Joe W. Gray, PhD
Lawrence Berkeley National Laboratory
Berkeley, CA |
|
| |
|
|
| 4:20 |
Physical activity and breast cancer: Evolution of a hypothesis
Leslie Bernstein, PhD
City of Hope National Medical Center
Duarte, CA |
|
| |
|
|
| 5:00-7:00 |
POSTER DISCUSSION SESSION 1 & RECEPTION – Ballroom B
|
|
| |
Circulating Tumor Cells |
101-110 |
| |
Daniel Hayes, MD, Moderator
University of Michigan, Ann Arbor, MI |
|
| |
|
|
| 5:00-7:00 |
POSTER SESSION
1 & RECEPTION – Exhibit Hall B
|
|
| |
(#1001-1119) |
|
| |
|
|
| |
Detection and Diagnosis
Mammography/Imaging
Screening |
1001-1033
1034-1040
|
| |
|
|
| |
Prognosis and Response Predictions
Prognostic Factors I
|
1041-1074 |
| |
|
|
| |
Treatment
Chemotherapy - General
Chemotherapy - Support
Psychosocial Aspects
|
1075-1087
1088-1090
1091-1101 |
| |
|
|
| |
Tumor Cell Biology
Angiogenesis
Antigens and Markers
Growth Factors/Inhibitors |
1102-1109
1110-1112
1113-1119 |
| |
|
|
| 7:00-10:00 |
SUSAN G. KOMEN
FOR THE CURE BRINKER AWARDS FOR SCIENTIFIC DISTINCTION DINNER
- Henry B. Gonzalez Convention Center - Ballroom C |
|
| |
Susan G. Komen for the Cure proudly presents the 2007 Brinker Awards for Scientific Distinction featuring special guest and keynote speaker Ambassador Nancy G. Brinker.
“Towards a Culture of Discovery: Progress and Passion in the Search for the Cures” will be an evening to remember as we celebrate Susan G. Komen for the Cure’s 25th anniversary, congratulate the 2007 Brinker Award Recipients, Joe W. Gray, PhD and Leslie Bernstein, PhD and honor the great achievements of our past Brinker Laureates – Henry B. Gonzalez Convention Center – Ballroom C.
Please purchase your tickets to the 2007 Brinker Dinner when registering at www.sabcs.org. You may also purchase your tickets onsite at the Susan G. Komen for the Cure booth. Tickets will be awarded on a first-come, first-served basis.
If you have additional questions, please contact sdeland@komen.org. We look forward to seeing you in San Antonio! |
|
|
Home
Registration
Schedule at a Glance
